Omeros Corp.

As of November 9, 2022, Omeros Corp. is overvalued with a negative Price to Book Value of -1.03 and a troubling ROCE of -120.45%, significantly lagging behind peers like Rigel Pharmaceuticals, and has seen a year-to-date stock decline of 67.71%.

As of June 17, 2025, the technical trend is mildly bearish, indicated by bearish MACD and moving averages, mixed KST signals, and Bollinger Bands, suggesting a cautious approach as the stock remains well below its 52-week high.

As of March 2022, Omeros Corp.'s management team includes Dr. Gregory Demopulos as Chairman, President, and CEO, with Mr. Thomas Cable as Lead Independent Director and several Independent Directors: Dr. Peter Demopulos, Mr. Ray Aspiri, Dr. Thomas Bumol, and Mr. Arnold Hanish.

Omeros Corporation is a biopharmaceutical company focused on developing therapeutics for inflammation, complement-mediated diseases, and central nervous system disorders. It has a market cap of $188.08 million and reported a net profit loss of $38 million as of March 2025.

As of Jun 18, Omeros Corp. has a market capitalization of 188.08 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -176.33 million over the last four quarters. The balance sheet as of Dec'24 shows shareholder's funds of -182.61 million and total assets of 277.08 million.